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medicine procurement in Austrian hospitals -
a primary survey of official and actual medicine
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Background: Knowledge about the prices of medicines used in hospitals, particularly the actually achieved ones, is
scant. There are indications of large discounts and the provision of medicines cost-free to Austrian hospitals. The
study aims to survey the official and actual prices of medicines procured by Austrian hospitals and to compare
them to the out-patient prices.
Methods: Primary price collection of the official hospital list prices and the actually achieved prices for 12 active
ingredients as of the end of September 2009 in five general hospitals in Austria and analysis of the 15 most
commonly used presentations.
Results: The official hospital list prices per unit differed considerably (from 1,500 Euro for an oncology medicine to
0.20 Euro for a generic cardiovascular medicine). For eight on-patent medicines (indications: oncology, anti-
inflammatory, neurology-multiple sclerosis and blood) actual hospital medicine prices equaled the list prices (seven
medicines) or were lower (one medicine) in four hospitals, whereas one hospital always reported higher actual
prices due to the application of a wholesale mark-up. The actual hospital prices of seven medicines (cardiology and
immunomodulation) were below the official hospital prices in all hospitals; of these all cardiovascular medicines
were provided free-of-charge. Hospital prices were always lower than out-patient prices (pharmacy retail price net
and reimbursement price).
Conclusion: The results suggest little headroom for hospitals to negotiate price reductions for “monopoly
products”, i.e. medicines with no therapeutic alternative. Discounts and cost-free provision (loss leaders) appear to
be granted for products of strategic importance for suppliers, e.g. cardiovascular medicines, whose treatment tends
to be continued in primary care after discharge of the patient.
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In European countries pharmaceutical policies have usu-
ally been addressed to the out-patient sector which is
also reflected in literature about system descriptions,
analyses and evaluations [1-7]. Since pharmaceutical ex-
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reproduction in any medium, provided the oryears (usually 5-10% of a nation’s medicines budget), it
has for a long time not been a priority of policy
makers [8]. Research on the hospital sector focused on
identifying costs of clinical events, economic evaluations
of alternative interventions as well as methodology work
for exploring elements of hospital costs [9-13]. However,
the prices of medicines procured in hospitals have not
been within the scope of research.
Recently, hospital medicines, including their price
components, started to attract the attention of policy
makers. This may be attributable to the growth ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(e.g. introduction of new, expensive medicines). Further,
it is generally acknowledged that medication started dur-
ing the hospital stay can impact the future medicines
prescribed after a patient has been discharged [14-21].
In Austria, the pharmaceutical sector is organized in a
two-tier system with different public payers for the out-
patient (i.e. community care) and the hospital sectors.
Medicines prescribed for use in the out-patient sector are
funded by the sickness funds; the decision about their in-
clusion in the reimbursement list (“Erstattungskodex”,
EKO) is done after a pharmacological, medical-therapeutic
and health-economic evaluation [22,23]. Medicines in
hospitals are financed out of the hospital budgets and
are, apart from some exemptions, included in the Diag-
nosis Related Groups (DRG) remuneration system.
Almost half of the hospitals in Austria are so-called
“Fondskrankenanstalten” (“fund hospitals”): These pub-
lic and private non-profit hospitals for public benefit
are financed by the Provincial Health Funds which re-
ceive funds from the federal government, the provinces,
local authorities and the social insurance institutions
[24]. Costs for reimbursed medicines used in out-
patient care are covered by the Social Health Insurance,
except for the prescription fee which is paid out-of
pocket by the patient [22,23,25].
In Austria, medicine prices are regulated in specific
settings: At ex-factory price level, the prices of medicines
to be used in the out-patient sector are subject to price
control if the manufacturer seeks reimbursement. To set
the price, the method of external price referencing
(international price comparison) is applied, and prices
must not exceed average of the prices in other European
Union Member States [22]. If a company launches a
medicine only in the hospital setting, then external price
referencing is not applicable since there is free pricing: the
manufacturer can determine the price of the medicine.
As distribution remuneration statutorily regulated
wholesale mark-ups and pharmacy mark-ups are added
on the ex-factory price [26]. This is primarily relevant
for the out-patient sector. Hospital pharmacies normally
do not dispense medicines to out-patients; however five
of the total of 46 Austrian hospital pharmacies also act
as a community pharmacy: when they dispense to out-
patients, they apply the mark-up regulation for commu-
nity pharmacies. Wholesale mark-ups are of marginal
importance in the in-patient sector because Austrian
hospitals are predominantly supplied directly by manu-
facturers and not via wholesalers [24].
Hospital prices are expected to be lower since hospi-
tals purchase medicines from the manufacturers and are
supposed to achieve discounted prices compared to the
medicine prices applied in the out-patient sector
throughout the country. However, the actually achievedprices by hospitals are not published by the hospitals
whereas the official prices applied in the out-patient sec-
tor are publicly available following the provisions for
publication of the Transparency Directive [27].
In the last decades, price analysis methodology has
been improved, and price surveys and comparisons both
at European and international level were undertaken by
commercial companies (e.g. IMS Health), international
institutions such as the Organisation for Economic Co-
operation and Development (OECD) and the World
Health Organization (WHO) [28,29], as well as by aca-
demics [30-32]. Further, in many European countries
public authorities responsible for pharmaceutical pricing
established their own systems of price surveys which is
needed when they compare to the prices of other coun-
tries in setting the price of a medicine in their country
[33]. Austria, which, as described, applies external price
referencing, also established a national price survey sys-
tem. Based on a regulation in the Austrian General
Social Insurance Law [34], the Austrian Health Institute
runs the national “Pharma Price Information” (PPI) ser-
vice of medicine prices in all EU Member States which
supports the Austrian Pricing Committee which is in
charge of calculating the EU average price [35].
Despite these advances in price analyses and compari-
sons, to the best knowledge of the authors, all price
comparisons available in English or German are, with
one exemption, limited to out-patient medicine prices.
We are aware of only one unpublished European price
survey for hospital medicines which, commissioned by
the Danish Ministry of Health, was undertaken for eight
countries (Canada, Denmark, England, France, Germany,
Norway, the Netherlands, Sweden) (COWI: Analysis of
hospital pharmaceuticals, unpublished). For Austria, no
survey of medicine prices in the in-patient sector has
been published yet.
This study aims to address this gap by surveying the
prices of medicines used in Austrian hospitals. The ar-
ticle will report both the official list prices and the actual
prices achieved in medicine procurement in hospitals
and compare them to the prices applied in the out-
patient sector.
Methods
The methodology for the price survey was elaborated in
the framework of the European Commission co-funded
project PHIS (Pharmaceutical Health Information Sys-
tem) which aimed to improve knowledge about in-
patient and out-patient pharmaceutical systems in all EU
Member States [36]. The PHIS activities included a price
comparison of medicine prices in hospitals of five
selected countries (Austria, the Netherlands, Norway,
Portugal, and Slovakia). Therefore, we developed a
methodology for price collection and international
Table 1 List of active ingredients selected for the survey
No. Active ingredient ATC code Key therapeutic area
1 Trastuzumab L01XC03 oncology
2 Docetaxel L01CD02 oncology
3 Rituximab L01XC02 oncology
4 Etanercept L04AB01 rheumatoid arthritis
5 Imatinib L01XE01 orphan/oncology
6 Immunoglobulin J06BA02 immunomodulation
7 Infliximab L04AB02 anti-inflammatory
8 Interferon beta-1α L03AB07 neurology-multiple sclerosis
9 Amlodipin C08CA01 cardiology
10 Simvastatin C10AA01 cardiology
11 Atorvastatin C10AA05 cardiology
12 Clopidogrel B01AC04 blood
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Leopold C, Morak S, Mazag J, Zimmermann N: PHIS
Hospital Pharma Methodology Paper; unpublished).
The methodology was elaborated by the authors in
spring 2009, revised after feed-back of the PHIS project
management team and the project Advisory Board in
summer 2009.
Definitions
This paper uses the terminology as defined in the gloss-
ary on pharmaceutical terms developed by the WHO
Collaborating Centre for Pharmaceutical Pricing and Re-
imbursement Policies [37]. Definitions of price types are
explained in the text or below the tables and graphs.
Selection of medicines
A multi-phase approach was applied for the selection of
the molecules for the price data collection. We only
considered medicines which were authorized for the
Austrian market. We focused our sample on active in-
gredients which account for a comparatively high share
within the hospitals’ budgets. For identifying the active in-
gredients accounting for the highest expenditure in the
in-patient sector in 2007 or 2008 (when available), we ana-
lyzed the Top 10 lists of the five countries included in the
PHIS price comparison, which were provided by country
experts, mostly from public authorities [24,38-41].
The molecules of this draft sample were checked to
see if they complied with the criteria of “commonly
used”, “standard therapeutic groups” and “high diagnos-
tic relevance”. Additionally, the sample was extended by
medicines which might impact the pharmaceutical bill of
the countries due to high consumption (e.g. high volume
products in the out-patient sector such as cardiovascular
medicines). Based on this selection process, the follow-
ing groups were taken into consideration: cardiovascular
medicines, contrast media, hematology medicines, neu-
rology medicines (especially for Multiple Sclerosis), nu-
trition (electrolyte), oncology medicines (breast, colon,
leukemia), and transfusion medicines.
Furthermore, we looked at which active ingredients
were investigated in other projects. Three price surveys
were considered as relevant reference work: the COWI
report (COWI: Analysis of hospital pharmaceuticals, un-
published), the voluntary internal price exchange exer-
cise INFOPRICE among EU Member States in the
framework of the Transparency Committee, and an or-
phan medicines survey (Habl C, Bachner F: Orphan
medicines survey, unpublished). We aimed to achieve a
balance between the on-patent and off-patent segments.
For methodological reasons we decided to disregard
medicines whose prices were difficult to compare, e.g.
due to different dosage forms or bulk packages in the
different countries.As a result, we compiled a list of 20 active ingredients.
However, we performed the survey on the first 12
ranked active ingredients only (see Table 1) because we
did not want to burden the hospital staff with a time-
intensive survey.
Selection of hospitals
We undertook the price survey in five hospitals in five
different Austrian provinces. All establishments are
general hospitals, and they are considered as public hos-
pitals (4 are owned by the provinces, and one is a non-
profit hospital owned by a religious institution). Table 2
describes the main characteristics of the five selected
hospitals compared to the hospitals throughout the
country. In many respects the hospitals of the sample
have identical or similar features as most hospitals in
Austria. A major difference, however, regards the hos-
pital pharmacy which four of the five sample hospitals
run; this is only the case in less than 20% of Austrian
hospitals [24]. The majority of hospitals in Austria, and
also one hospital of this price survey, organise their
medicines supply management via a “pharmaceutical
depot” which is a unit within the hospital for the internal
supply of the hospital with medicines. A “pharmaceutical
depot” usually has fewer tasks, competences and respon-
sibilities than a hospital pharmacy, and it might be run
by the hospital pharmacy of another hospital [24].
Price survey methodology
We collected the price data and other required informa-
tion during study visits to the Austrian hospitals. For
doing so, we developed a price survey template and a
questionnaire to guide through interviews.
The price survey template comprised fields on the se-
lected products and for surveying price data as well as
Table 2 Characteristics of the hospitals included in the survey
Parameter Hospitals of the price survey Hospitals in total in Austria
Number of hospitals 5 266 (December 2008)
Type of hospitals and
geographic distribution
All are general hospitals; 1 in Vienna, 1 in the South East of
Austria, 1 in the South, 1 in the North Western part, 1 in the
biggest province of Austria
38% of all hospitals were general hospitals (2007)
Ownership All are public hospitals; 4 are owned by Austrian provinces,
1 is in the ownership of a non-profit religious congregation
Around 60% of hospitals are public
Size of hospitals 4 are big hospitals (> 500 acute care beds); 36 hospitals with more than 400 acute care beds
One hospital is middle sized (between 400 and 500 acute
care beds)
Hospital pharmacy 4 hospitals have a pharmacy; 17% of all hospitals have a hospital pharmacy (2008).
The other, often smaller hospitals are equipped with a
pharmaceutical depot1 hospital has a “pharmaceutical depot” which is delivered by
a wholesaler with an affiliated pharmacy1
Purchasing policies Negotiations are the key policy for purchasing medicines in
the 5 hospitals.
Same situation for all hospitals in Austria – tendering of
medicines is only done in rare cases, but a rising trend
can be observed
Tendering by hospitals is of minor importance in 4 hospitals;
1 hospital commissioned a wholesaler following a tendering
process
Level of centralisation in
purchasing
Decentralised purchasing (purchasing at hospital level or at the
hospital owner level)
Same situation for all hospitals in Austria
Pharmaceutical
expenditure in % of total
hospital expenditure
Around 7% of the hospital expenditure Around 9% of the hospital expenditure
1 Pharmaceutical depots are only allowed to purchase the required medicines from another licensed pharmacy in the European Economic Area (EEA).
Source: Reference data on Austria in total from [15].
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medicines. We pre-filled the trade name of the selected
active ingredients, the ATC code and – if possible – the
manufacturer name. We asked for the official hospital
list prices and the actual (negotiated) hospital prices
(including and excluding value-added tax) of the medi-
cine packs as of 30 September 2009. In the cases of
off-patent medicines, with different products being
available, we surveyed the most expensive product
(usually the original medicine) and the least expensive
one. Further, we collected additional explanatory infor-
mation on discounts, rebates or other arrangements
such as cost-free medicines or rebates in kind.
The questionnaire for the accompanying interviews
contained questions related to the hospital and hospital
pharmacy (delivery chain and pharmaceutical provision
in that hospital, funding of medicines, monitoring activ-
ities by the hospital pharmacy, initiatives for a more ra-
tional use of medicines and initiatives to improve
cooperation at the interface of hospital and out-patient
care, for example).
On average, the study visits took about three hours
per hospital. In all cases the chief/responsible hospital
pharmacists of the hospital pharmacies, and in one case
a “pharmaceutical depot”, personally provided the price
data and were available for the interview. In return for
providing data, the hospital pharmacists were ensured
anonymity.Price analysis
The data collection yielded a wide variety of presenta-
tions of different pharmaceutical forms, strengths and
pack sizes. For each active ingredient we identified one
specific product in a common pharmaceutical form,
strength and pack size which we compared to a medi-
cine of the identical or similar pharmaceutical form,
strength and pack size in the other hospitals. The price
of a medicine in a specific form and package size with
most reported prices in the hospitals (defined as “most
commonly used” presentations) was selected for the ana-
lysis. Even if we had collected prices of many more pre-
sentations (e.g. different pack sizes), these were excluded
due to missing reference products in the other hospitals.
Hospital prices were analyzed as net prices, i.e. exclu-
ding the value added tax, and as “unit prices” (i.e. per
tablet, vial) to allow for a comparison in case of different
pack sizes (e.g. 28 and 30 tablets). Possible rebates
granted by specific companies ex-post, e.g. at the end of
a year if a certain volume had been purchased, could not
be taken into account.
The relevant comparator price types applicable for
medicines used in out-patient care were the ex-factory
price, the pharmacy retail price net and the reimburse-
ment price (“Kassenpreis”) as of 30 September 2009:
The pharmacy retail price is applicable at community
pharmacy level, and the reimbursement price is the price
which Austrian sickness funds pay for the medicine in
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For seven of the 15 medicines surveyed, only the original
products were available on the Austrian market. Where
generic alternatives were available, in two cases (simva-
statin, immunoglobulins) all hospitals applied generic pre-
sentations, in one case (atorvastatin) all hospitals used the
original products, and in the case of amlodipidin four of
the five hospitals opted for the original products. Two
competitors for Interferon beta-1α were on the marketTable 3 Prices (per unit) for 12 active ingredients in Austrian
Active ingredient O/G1
Oncology
Trastuzumab 150 mg powder for concentrate for solution f. infusion O
Docetaxel 1 × 2 ml 80 mg/2 ml concentrate and solvent for
solution for infusion
O
Rituximab 500 mg concentrate and solvent for solution for infusion O
Imatinib 400 mg tablets (30 tabs) O
Cardiology
Amlodipin 5 mg tablets (28 units) O
Amlodipin 5 mg tablets (28 units) G
Simvastatin 20 mg tablets (30 units) G1
Simvastatin 20 mg tablets (30 units) G2
Atorvastatin 20 mg tablets (30 units) O
Rheumatoid arthritis
Etanercept 1 ml (50 mg/ml) solution for injection in a prefilled pen O
Immunomodulation
Immunoglobulin 100 mg/ml, solution for injection in vial (50 ml) G1
Immunoglobulin100 mg/ml, solution for injection in vial (50 ml) G2
Anti-inflammatory
Infliximab 100 mg powder for concentrate for solution for infusion O
Neurology-multiple sclerosis
Interferon beta-1α 1 × 0.5 ml (44 mcg/0.5 ml) solution for
injection – prefilled pen
O
Blood
Clopidogrel 75 mg tablets (28 units) O
1 O original product, G generic; in case of more than one generic, numbering of the
2 Equals the ex-factory price for out-patient medicines. No range, as this is the sam
3 The (actual) price or amount paid by a hospital (or hospital pharmacy) in order to
tax (VAT).
4 The price charged by retail pharmacies to the general public. It includes any phar
5 Reimbursement price paid by Austrian sickness funds, called “Kassenpreis”. Howev
reimbursement list (“Erstattungskodex”, EKO). Therefore the indicated out-patient pand both were used in three of the five surveyed hospi-
tals. As a result, 15 presentations in an identical
pharmaceutical form – for the sake of readability re-
ferred to hereafter as “products” or “medicines” – were
subject to the analysis.
Table 3 presents the prices expressed per unit for the
15 products in the surveyed hospitals compared to the
out-patient sector. The ex-factory prices for medicines
in out-patient use are not indicated separately as the of-
ficial hospital prices correspond to them. For two indica-
tions which were represented by a higher number of
medicines in the sample (oncology, cardiology) the price
data results are separately presented in Figure 1.hospitals and in out-patient care












Prices as of 30 September 2009
690.- 690.- – 713.81 932.18 748.60
654.06 622.90 – 663.67 885.68 711.30
1516.43 1516.43 2001.36 1607.30
84.87 84.87 (n = 4) 111.12 89.24
0.29 0.00 (n = 4) 0.55 0.44
0.20 0.00 (n = 1) 0.41 0.32
0.26 0.00 (n = 2) 0.49 0.40
0.23 0.00 (n = 3) 0.45 0.40
1.10 0.00 1.94 1.56
242.53 242.53 (n = 2) 323.65 259.93
246.18 185.- – 190.- (n = 4) 348.36 279.20
219.40 160.- – 185.- 310.45 248.85
565.50 565.50 (n = 4) 762.32 612.20
81.25 81.25 (n = 3) 107.68 86.48
1.64 1.64 – 1.71 2.90 2.32
generics (G1, G2).
e in all hospitals.
take delivery of certain unit of medicines. The price excludes the value added
macy mark-up or dispensing fee. The net price excludes VAT.
er, seven of the selected products are not included in the out-patient
rices are rather of theoretic character.
Figure 1 Price differences of oncology and cardiovascular medicines between in the hospital and out-patient sectors.
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The sample of the 15 medicines varied from high-priced
medicines (mainly in oncology) with ex-factory prices
(official hospital list prices) per unit of several hundreds
of Euros to low-priced medicines around 0.25 Euro (in
cardiology). The highest priced medicine of the sample
was rituximab 500 mg with an ex-factory price per unit
of 1,515.- Euro, whereas a generic version of amlodipin
5mg (priced 0.20 Euro per tablet) was at the other end
of the range.
The actual hospital prices were lower; some medicines
were provided cost-free to all hospitals.Actual hospital prices compared to official hospital prices
In the case of seven medicines (trastuzumab 150 mg,
rituximab 500 mg, imatinib 400 mg, etanercept 50 mg,
infliximab 100 mg, Interferon beta-1α, clopidogrel 75 mg),
the actual hospital prices equaled the hospital list prices,
or they were, in one hospital, even higher than official
hospital list prices due to the application of a wholesale
mark-up.
For docetaxel 1×2 mg 80 mg/2 ml this hospital, sup-
plied by a wholesaler, also reported a 2% higher actual
hospital price compared to the official list price, whereas
the other four hospitals had lower actual hospital prices
than official list prices. Three hospitals reported recei-
ving rebates in kind (i.e. for 20 vials they get one free).
For the remaining seven products, the actual hospital
prices were lower than the official hospital prices in all
hospitals: two medicines for immunomodulation (im-
munoglobulins 100 mg/ml in two different pharmaceut-
ical forms) had a 15%-27% lower price. Five medicines(all cardiology medicines: amlodipin, simvastatin, ator-
vastatin) were provided cost-free to the hospitals, inde-
pendently of whether they were original products or
generics.
While for high-priced oncology medicines hospitals
could not achieve any discounts, cardiology medicines of
the sample were provided for free (Figure 1).Price range among the hospitals
As the official hospital list price corresponds to the ex-
factory price, the surveyed list prices for identical medi-
cines did not differ among hospitals.
Few differences in the actual hospital prices of identical
medicines were observed among the surveyed hospitals.
Differences were found for five products of the sample
(trastuzumab 150 mg, docetaxel 1×2 mg 80 mg/2 ml,
two presentations of immunoglobulin 100 mg/ml, and
clopidogrel 75 mg). In the case of trastuzumab 150 mg,
docetaxel 1×2 mg 80 mg/2 ml and clopidogrel 75 mg
the actual hospital prices were identical in four hospi-
tals whereas the fifth hospital the medicines had a
higher actual hospital price.
Further, we noticed differences in the official list prices
and actual hospital prices of different generic products
of the same active ingredient in an identical presentation
(i.e. in the same strength and pack size). This was the
case for two products (simvastatin and immunoglobu-
lins) where hospitals reported purchasing different pro-
ducts: For simvastatin the hospital list prices ranged
between 0.23 and 0.26 Euro per unit, but all hospitals re-
ceived these products for free. Hospital list prices for the
immunoglobulins in the same pharmaceutical presentation
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pending on the purchased brand. Actual hospital prices
for these products also showed price variations (between
160 and 190 Euro) among hospitals, but the actual prices
were always lower than the list prices.
Hospital prices compared to out-patient prices
The surveyed pharmacy retail prices net were always
higher than the prices applied in the hospital setting –
regardless of the surveyed price types in hospitals. Also,
the out-patient reimbursement prices (“Kassenpreis”) al-
ways exceeded the hospital prices.
As shown in Figure 1, the smallest difference between
the official hospital list price and the out-patient prices
was observed for the high-price product rituximab
500mg (reimbursement price: +6% and pharmacy retail
price: +32% compared to the hospital list price) and the
largest difference for a generic version of amlodipin
5mg (reimbursement price: +58% and pharmacy retail
price: +106%).
Discussion
Our study was the first price survey undertaken for
medicines used in hospitals in Austria. It was done for a
sample of 12 active ingredients in a few hospitals. Even
though we collected several price data points, our sam-
ple of comparable presentations (in the same pharma-
ceutical form, strength and pack size) was rather small,
and sometimes the “most commonly used form” identi-
fied for the comparative analysis was not used in all hos-
pitals surveyed. We acknowledge the limitations with
regard to the number of products and hospitals, and we
are aware that, as some of the products are only used in
hospitals and not even included in the out-patient reim-
bursement list (“Erstattungskodex”, EKO), the compari-
son of the hospital prices to the out-patient prices could
be considered as only of theoretical character for these
products.
Despite these limitations, we believe that this price
survey provides added value to the scientific community
and to policy makers: Our study contributes consider-
ably to transparency since no price survey for medicines
in hospitals had been published before. Additionally, it
brings attention to an area of health care which is of
major relevance both economically and in terms of qual-
ity. Further, we developed and piloted a methodology
which can easily be adopted and used for future surveys
in Austria and other countries with a similar health care
system (e.g. European Union Member States).
The development of a methodological design was a
key prerequisite from a technical point of view. Another
requirement was the building of trust with the hospital
pharmacists, who were the data providers, and the estab-
lishment of a common understanding of the study’srationale. In Austria, though hospital pharmacists appear
to be well connected, in particular via the associations
(Austrian Association of Employed Pharmacists, Austrian
Association of Hospital Pharmacists), prices of medicines
are not officially shared among them nor are they pub-
lished, so the communication of price data to us as exter-
nal people was a considerable indicator of trust.
The lack of transparency about the medicine prices
paid by hospitals can, to some extent, be explained by
the procurement policies in Austria. A major part of
medicines is purchased in a decentralized way, mostly
directly from the manufacturer, by the individual hospi-
tals; and the price is the outcome of negotiations. There
are initiatives of joint purchasing, in particular for high-
cost medicines, by the hospital owner organizations. The
use of tenders is still low, but increasing in Austria [24].
There is a similar pattern in the procurement of medi-
cines for hospitals in Germany and in several Central
and Eastern European countries, whereas tendering of
medicines, in many cases done at central or regional
level, is the key purchasing strategy in the remaining EU
Member States [8,15]. Procurement based on negotia-
tions, in particular at the level of individual hospitals,
might negatively impact the transparency of prices since
the purchasers are told by the suppliers that they
would be granted the best prices if they in return
agreed to keep them confidential. However, our results
could not confirm better prices for individual hospitals
since price differences among hospitals were identified
in very few cases.
For the out-patient sector, well-developed and tested
approaches for price surveys exist [28-31,42]. Developing
the survey methodology, we had to understand if there
is a price type of the out-patient sector to which the hos-
pital list price and the actual price might correspond.
Our assumption that the official hospital list price in
Austrian hospitals equals the ex-factory price was con-
firmed by the hospital pharmacists involved in the price
survey. No corresponding price type of the out-patient
sector could be identified for the actual hospital price
since it is a hospital specific price.
The survey of the actual prices also served to test the
hypothesis of the low actual hospital prices and the
provision of cost-free medicines (loss leaders) in Austrian
hospitals. We found some differences between the actual
hospital prices and the official prices (ex-factory prices).
These price differences were, however, observed for only
some, usually lower-priced medicines. In cases where
price differences were identified, the actual prices were, in
most hospitals, lower (or even zero), with the exception of
one hospital which had higher prices for specific, mostly
expensive on-patent medicines. This hospital had no hos-
pital pharmacy; the “pharmaceutical depot” in charge of
the provision of medicines in that hospital was supplied
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tributable to the wholesale mark-up which was included
in their actual prices.
While the extent of discounts granted did not differ
among the hospitals surveyed, the results revealed a pat-
tern with regard to the kind of medicines: In general, no
discounts could be negotiated for the high cost medi-
cines. This is, for instance, the case for three of the four
oncology medicines included in our sample, all of them
on-patent. The price survey results supported findings of
interviews performed with the hospital pharmacists be-
fore collecting the price data. Hospital pharmacists
stated that for medicines which “really count” (i.e. ac-
counting for a major part of the hospital pharmaceutical
budget) hospitals are not successful in negotiating dis-
counts, and they have to pay the full, i.e. ex-factory, price.
The study results suggest that there appears to be little or
no room for price reductions for “monopoly products”, i.e.
medicines with no therapeutic alternatives.
We acknowledge that ex-post rebates were not taken
into account in our price survey since they could not be
assessed by the data providers at the time of the price
data collection. Rebates are granted by the suppliers at
the end of the year, with reference to the sales volume of
a hospital. They are known to be a common commercial
instrument in European countries (e.g. Portugal) [15,39],
and their existence in Austria was confirmed by the
pharmacists of the sample hospitals.
Price reductions in the form of discounts (i.e. reflected
in the actual hospital prices) were observed whenever
therapeutic alternatives were available. These were ge-
nerics, but competition also appeared to be triggered by
original products considered as alternatives. We ob-
served this pattern for the immunoglobulins whose
lower actual hospital prices compared to their official
hospital list prices might be attributable to the choice of
different products (brands) available.
In Austria a cost-free provision of medicines to hospi-
tals is allowed and applied. This practice is forbidden in
some European countries (e.g. Denmark, Hungary, Italy,
Lithuania, and United Kingdom) [15], while there are no
explicit provisions in some others (e.g. Bulgaria) [43].
Discounts and rebates of up to 100%, which eventually
make the products cost-free, are known from a few
other countries (e.g. Portugal, Slovakia) [39,40]. In our
price survey on Austria, we found the provision of cost-
free medicines only in one indication: cardiology. But all
cardiovascular medicines of the sample, irrespective of
their patent status, were supplied cost-free.
The group of medicines to treat cardiovascular dis-
eases, which account for a high share in the disease bur-
den [44], could be characterized as “strategic medicines”
from the industry’s point of view. Cardiovascular medi-
cines account for high volumes in the out-patient sectorand thus contribute to high expenditure [45]. As the
starting treatment with specific (cardiovascular) medicines
by specialists impacts the future use [46], manufacturers
are interested to get the product applied already in hospi-
tals in order to initiate follow-up prescriptions in out-
patient setting [47].
Prioritization is most important when resources are
scarce [48]: Hospital pharmacists have to decide which
medicines (high-cost medicines for few patients or a lar-
ger quantities of lower-priced medicines for larger pa-
tient populations) they will purchase given the limited
budgets, and whether they agree to receive discounted
and cost-free medicines in spite of the negative impact
for the overall health care system. Particularly in the
case of financial pressure, hospital pharmacists, who are
accountable to the hospital management, are happy
about any savings achieved by discounted and cost-free
medicines. They are aware of the fact that with accepting
free-cost medicines they impact the continuing treat-
ment with these products after discharge of the patient
(personal communication). Their procurement strategies
result from dual financing, with different payers for the
pharmaceutical bill in the out-patient and hospital sectors.
The authors see a need for the development and imple-
mentation of effective policy options which could improve
the medicines management at the interface of hospital and
out-patient sector. Good practice examples from other
countries (e.g. joint reimbursement lists in Stockholm
County [49], or Scotland [50]) might serve as models.
The hospital sector has often been criticized for its as-
sumed lower hospital prices compared to the out-patient
sector and for cost-free medicines. Our price collection
confirmed that hospital prices, even if not discounted,
are always lower than out-patient retail prices – irre-
spective of the out-patient price type (pharmacy retail
price or reimbursement price). This is attributable to the
involvement of more distribution actors in the out-
patient sector and their statutory remuneration for the
cost for handling distribution. The different price levels
in the in-patient and out-patient sectors, which is
explained by these factors, is not of concern for policy
makers, but the critical issue is that, via the practice of
granting discounts and providing cost-free products, the
treatment of patients is likely to be started with medi-
cines which account for high volume and eventually high
expenditure where medication is continued with these
products in the out-patient sector.
Conclusions
The study offers, for the first time in Austria, informa-
tion about medicine prices in hospitals, and thus con-
tributes to transparency. The suppliers’ argument of
granting better prices to a hospital in return for confi-
dentiality could not be confirmed. Discounts and rebates
Vogler et al. Cost Effectiveness and Resource Allocation 2013, 11:15 Page 9 of 10
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suggest that there is no or little room for price reduc-
tions on “monopoly products”, for which no therapeutic
alternatives are available. The study confirmed the prac-
tice of providing loss leaders to hospitals, particularly in
strategic relevant therapeutic areas where medication is
supposed to continue in the out-patient treatment. The
starting treatment in a hospital with a higher priced
medicine is expected to increase resource pressure in
the out-patient sector, and to cause concern among pa-
tients if their therapies are switched, potentially leading
to irritation and confusion with medicine regimens, par-
ticularly in the elderly.
The strategies applied by the different stakeholders (e.g.
pharmaceutical industry, hospital pharmacists, payers) are
influenced by the underlying organization of the Austrian
health care system which is characterized by different
payers in the different sectors (dual funding). The results
of the price survey call for interface management initiatives
to improve the coordination and cooperation between the
in-patient and out-patient sectors. Policy makers are urged
to develop and implement appropriate policies.
The study should be considered as a starting point to
continue improving transparency about medicine prices
in the in-patient sector. Further research, e.g. involving
more hospitals, broadening the sample of products, is
recommended.
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